Teva Xtampza Settlement Brings Potential Three-Year Head Start
Suit In Delaware Court Settled With 2033 Date
Executive Summary
Teva is lining up another complex ANDA product after agreeing to settle litigation with Collegium Pharmaceutical over the Israeli firm’s proposed generic version of Xtampza ER (oxycodone) extended-release capsules.
You may also be interested in...
Teva Still Hopes To Reach Deal On US Price-Fixing Allegations
Teva says it remains hopeful that it can resolve US price-fixing allegations “in a positive way” with the US Department of Justice, but acknowledges that the matter could go all the way to trial.
US FDA Releases Slew Of Guidances On A Fell Day For Complex Generics
New and updated guidances are good news for ANDA sponsors, but timing – coming the day Sandoz announced a CRL for its Advair copy – underscores challenges that developers of complex generics face.
American Regent’s Vasopressin Questioned As Eagle Prepares ANDA Launch
With Eagle set to launch its long-awaited vasopressin ANDA product on 17 January, the US firm’s management told investors it was unsure what its launch meant for the 505(b)(2) rival product in the hands of American Regent.